Just In
- 5 hrs ago Summer Fashion: Your Bollywood Style White Outfits Guide To Keep It Cool And Chic
- 6 hrs ago Sonam Kapoor Stuns In A Huisang Zhang Skirt Set, A Skirt-Top Style Guide From The OG Fashionista!
- 10 hrs ago Thrissur Pooram 2024: Date, Time, History, Significance, And Celebrations Related To Kerala's Rich Traditions
- 14 hrs ago Daily Horoscope, 19 April 2024: Gemini Will Have A Controversial Day In Terms Of Love
Don't Miss
- Movies Kareena Kapoor Inspired Blouse Back Designs, Explore Top 5 Hottest Picks For This Wedding Season
- News Iran Embassy In Paris Cordoned Off Following Reports Of Suspect With Explosives
- Sports IPL 2024 LSG vs CSK Live Score, Match 34 Latest Updates: Lucknow Super Giants Choose To Bowl First
- Finance Gold Prices In US: Yellow Metal Rates Surge Amid Escalating Tensions In Middle East; Hit Record High
- Automobiles Suzuki Swift Hatchback Scores 4 Star Safety Rating At JNCAP – ADAS, New Engine & More
- Education NLSIU Announces the Rajiv K. Luthra Foundation Grant
- Technology Dell Introduces AI-Powered Laptops and Mobile Workstations for Enterprises in India
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
Nano Bubbles In Blood Of Covid Patients Could Treat, Prevent Infection With Coronavirus Variants
Scientists in the US have identified tiny natural bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients that can block infection from broad strains of the SARS-CoV-2 virus.
The evACE2 are lipid vesicles in nanoparticle size that express the ACE2 protein on cells. These bubbles act as decoys to lure the SARS-CoV-2 virus away from the ACE2 protein, which acts as a gateway for the virus to infect cells.
The evACE2 can serve as a therapeutic to be developed for prevention and treatment for current and future strains of SARS-CoV-2 and subsequent coronaviruses, the researchers said.
Once developed as a therapeutic product, evACE2 have the potential to benefit people as a biological treatment with minimal toxicities, they said.
The study, published in the journal Nature Communications on Thursday, is the first to show evACE2 are capable of fighting the new SARS-CoV-2 variants with an equal or better efficacy than blocking the original strain.
The researchers found that evACE2 exist in human blood as a natural anti-viral response. The more severe the response, the higher the levels of evACE2 detected in the patient's blood.
"Whenever a new mutant strain of SARS-CoV-2 surges, the original vaccine and therapeutic antibodies may lose power against Alpha, Beta, Delta and the most recent, Omicron," said the study co-senior author Huiping Liu, an associate professor at Northwestern University.
"However, the beauty of evACE2 is its superpower in blocking broad strains of coronaviruses, including current SARS-CoV-2 and even future SARS coronaviruses from infecting humans," Liu said.
The study in mice demonstrates the therapeutic potential of evACE2 in preventing or blocking SARS-CoV-2 infection when it is delivered to the airway via droplets, the researchers said.
The SARS-CoV-2 spike protein grabs evACE2 instead of cellular ACE2, preventing the virus from entering the cell, they said.
Once captured, the virus will either float harmlessly around or be cleared by a macrophage immune cell, no longer causing the infection, according to the researchers.
"The key takeaway from this study is the identification of naturally occurring extracellular vesicles in the body that express the ACE2 receptor on their surface and serve as part of the normal adaptive defence against COVID-19-causing viruses," said study co-senior author Raghu Kalluri from the University of Texas.
"Building upon this, we've discovered a way to harness this natural defence as a new potential therapy against this devastating virus," Kalluri said.
The researchers noted that the COVID-19 pandemic has been extended and challenged by a constantly changing SARS-CoV-2 virus.
One of the biggest challenges, they explained, is the moving target of pathogenic coronavirus that constantly evolves into new virus strains with mutations.
The team has a pending patent on evACE2. Their goal is to collaborate with industry partners and develop evACE2 as a biological therapeutic product - nasal spray or injection - for the prevention and treatment of COVID-19.
The researchers have formed a startup company, Exomira, to take this patent and develop evACE2 as a therapeutic.
- pregnancy parentingMysterious Pneumonia Outbreak In China: What Are The Long-Term Effects Of Pneumonia In Children?
- healthCan You Get Back COVID-Related Loss Of Sense Of Smell And Taste (Parosmia)? Looks Like You Can!
- healthDid Covid-10 Vaccination Increase Risk Of Sudden Deaths In Young Adults? ICMR Finds This..
- wellnessDelhi Air Pollution, Air Quality Very Poor: Do Covid Masks Help Reduce Pollution Side Effects?
- healthNobel Prize 2023: Scientists Behind The COVID-19 mRNA Vaccines Wins
- healthWhat Is Disease X? 20 Times More Deadlier Than Covid 19; Can Cause 50 Million Deaths, Does It Have Vaccine?
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- healthDo You Pick Your Nose? Stop! It Can Increase COVID Risk
- healthEris Variant: WHO Alarms New Covid Wave; Should India Be Concerned About This Pandemic
- healthVitamin D Deficiency Linked With Increased Risk Of Long COVID
- healthCOVID Surge In India: Do You Need A COVID-19 Booster Shot?
- healthCOVID-19: IMA Cites 3 Reasons Behind Recent Surge In Covid-19 Cases: What Are They?